NCT05222425 is a Phase 3 clinical trial of Xagrotin in Sars-cov-2, sponsored by Biomad AS.

Who is sponsoring NCT05222425?

NCT05222425 is sponsored by Biomad AS.

What drugs are being tested in NCT05222425?

Interventions in NCT05222425: Xagrotin, Green tea.

What condition does NCT05222425 study?

NCT05222425 studies Sars-cov-2.

Is NCT05222425 still recruiting?

NCT05222425 is currently status unknown. Last updated 17 March 2022.

Last reviewed 2022-03-17 · How we verify

NCT05222425

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Non-severe Covid-19 Outpatients With Xagrotin, Phase 3

Status unknown Phase 3 Last updated 17 March 2022

What this trial tests

Phase 3 trial testing Xagrotin in Sars-cov-2 in 3,000 participants. Status unknown.

Timeline

1 June 2022

Primary endpoint
15 October 2022

7 December 2022

Quick facts

Lead sponsor	Biomad AS
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	3,000
Start date	1 June 2022
Primary completion	15 October 2022
Estimated completion	7 December 2022
Sites	1 location across Iraq

Drugs / interventions tested

Xagrotin — full drug profile →
Green tea — full drug profile →

Conditions studied

Sars-cov-2 — all drugs for Sars-cov-2 →

Sponsor

Biomad AS — full company profile →

Who can join

Adults 18 to 99, any sex, with Sars-cov-2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an interventional, multi-center, randomized study. Adults with confirmed covid-19 disease not more than 10 days before enrollment date will be recruited (n=1000). Patients in same condition who get treated with standard of care will be randomly assigned to the control group (n=1000), and patients in same condition who get treated with standard of care will be randomly assigned to the placebo group (n=1000). The investigators analyze the effect of Xagrotin, and also investigate impact of different characteristics for instance gender, age, duration of disease, smoking habits and concomitant diseases on the outcome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Xagrotin

Trials testing the same drug.

NCT05017493 — Treatment of Covid-19 With a Herbal Compound, Xagrotin · Phase 1, PHASE2 · completed

Other Biomad AS trials

Trials by the same sponsor.

NCT05017493 — Treatment of Covid-19 With a Herbal Compound, Xagrotin · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05222425 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biomad AS
Last refreshed: 17 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05222425.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing